EGFR and lung carcinoma: Previous findings also reported the role of CAF-mediated resistance of lung cancer cells to EGFR tyrosine kinase inhibitors (TKI) erlotinib [64] and gefitinib [65] through the induction of an EMT phenotype, suggesting that a specific phenotype of podoplanin- [66] and CD200-expressing [67] CAFs is responsible for the constituting resistance to EGFR TKIs.